What is VSTM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.76B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VSTM?

P/E (TTM) is n/a and 52-week range is $3.43 to $10.82 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VSTM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VSTM?

The company profile lists revenue (TTM) near $77M, net income (TTM) near $-17.79B, EPS (TTM) near $-2.46 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Verastem Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Needham, Massachusetts, US, 87.9M shares outstanding, ISIN US92337C2035 when available from company profile and filing metadata.

Verastem Inc

$VSTM

Health Care · Biotechnology

IR Run Scenarios

$8.38

+3.33%

Verastem Inc

$VSTM

Health Care · Biotechnology

IR Run Scenarios

$8.38

+3.33%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Employees

102

Website

www.verastem.com/

IPO

2011-11-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US92337C2035

Headquarters

Needham, Massachusetts, US

Shares outstanding

87.9M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

101.44%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Employees

102

Website

www.verastem.com/

IPO

2011-11-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)